Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates
Preprint
- 21 April 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. The nonhuman primate (NHP) model of SARS-CoV-2 infection replicates key features of human infection and may be used to define immune correlates of protection following vaccination. Here, NHP received either no vaccine or doses ranging from 0.3 – 100 μg of mRNA-1273, a mRNA vaccine encoding the prefusion-stabilized SARS-CoV-2 spike (S-2P) protein encapsulated in a lipid nanoparticle. mRNA-1273 vaccination elicited robust circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced in bronchoalveolar lavages and nasal swabs following SARS-CoV-2 challenge in vaccinated animals and was most strongly correlated with levels of anti-S antibody binding and neutralizing activity. Consistent with antibodies being a correlate of protection, passive transfer of vaccine-induced IgG to naïve hamsters was sufficient to mediate protection. Taken together, these data show that mRNA-1273 vaccine-induced humoral immune responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP. One-Sentence Summary mRNA-1273 vaccine-induced antibody responses are a mechanistic correlate of protection against SARS-CoV-2 infection in NHP.Keywords
This publication has 42 references indexed in Scilit:
- Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virusPLoS Neglected Tropical Diseases, 2018
- Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responsesThe Journal of Experimental Medicine, 2018
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigenProceedings of the National Academy of Sciences of the United States of America, 2017
- Nomenclature for Immune Correlates of Protection After VaccinationClinical Infectious Diseases, 2012
- Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccinesJournal of Virological Methods, 2010
- Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infantsThe Journal of Pediatrics, 1992
- Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio VaccinesThe Journal of Infectious Diseases, 1991
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989
- Characteristics of the Immune Response to Poliovirus Virion Polypeptides After Immunization with Live or Inactivated Polio VaccinesThe Journal of Infectious Diseases, 1988
- Immunoglobulin Response in Serum and Secretions after Immunization with Live and Inactivated Poliovaccine and Natural InfectionThe New England Journal of Medicine, 1968